Bioresorbable barriers have been recently introduced in clinical practice for guided tissue regeneration therapy. One of these is the Guidor matrix barrier, which is made of amorphous polylactic acid softened with a citric acid ester to increase malleability and facilitate clinical handling. The advantages of the bioresorbable barrier include: the elimination of second surgery; better handling and adaptation around the totoh and over the bone; and integration of the connective tissue of the flap with the barrier, preventing epithelial migration, gingival recession, and pocket formation. In the case of matrix exposure the material disappears within 6 to 8 weeks. The purpose of this report is to present the clinical application of the Guidor matrix barrier in the treatment of two- or three-wall intrabony defects that were followed up for more than 1 year. The evaluation included soft tissue changes using clinical parameters and ahr d tissue changes using nonstandardized digital subtraction radiography. In the authors' opinion, the incorporation of a bioresorbable barrier in guided tissue regeneration therapy represents a significant improvement in the treatment of intrabony defects.